Justin Ferdinandus

3.6k total citations · 2 hit papers
51 papers, 2.3k citations indexed

About

Justin Ferdinandus is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Justin Ferdinandus has authored 51 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 32 papers in Radiology, Nuclear Medicine and Imaging and 22 papers in Oncology. Recurrent topics in Justin Ferdinandus's work include Radiopharmaceutical Chemistry and Applications (21 papers), Prostate Cancer Treatment and Research (21 papers) and Peptidase Inhibition and Analysis (14 papers). Justin Ferdinandus is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (21 papers), Prostate Cancer Treatment and Research (21 papers) and Peptidase Inhibition and Analysis (14 papers). Justin Ferdinandus collaborates with scholars based in Germany, United States and Australia. Justin Ferdinandus's co-authors include Shahneen Sandhu, John Violet, Michael S. Hofman, Declan G. Murphy, Tim Akhurst, Rodney J. Hicks, Amir Iravani, Scott Williams, Sue Ping Thang and Grace Kong and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Justin Ferdinandus

48 papers receiving 2.3k citations

Hit Papers

[177Lu]-PSMA-617 radionuclide treatment in patients with ... 2018 2026 2020 2023 2018 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
    2018 815 citations Michael S. Hofman, John Violet et al. The Lancet Oncology profile →
  2. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
    2018 339 citations John Violet, Price Jackson et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Justin Ferdinandus Germany 18 1.5k 1.5k 1.0k 424 330 51 2.3k
Carsten Kobe Germany 31 1.6k 1.1× 1.4k 1.0× 754 0.7× 233 0.5× 271 0.8× 187 3.0k
Jérémie Calais United States 37 2.7k 1.8× 3.5k 2.4× 1.3k 1.3× 857 2.0× 562 1.7× 218 4.9k
Laura Evangelista Italy 30 1.8k 1.2× 1.7k 1.2× 706 0.7× 415 1.0× 473 1.4× 224 3.3k
Sanjana Ballal India 24 1.1k 0.8× 692 0.5× 976 1.0× 266 0.6× 412 1.2× 88 1.9k
Hendrik Rathke Germany 26 1.7k 1.1× 1.1k 0.8× 2.0k 2.0× 880 2.1× 817 2.5× 52 3.1k
Madhav Prasad Yadav India 22 1.1k 0.7× 677 0.5× 963 1.0× 255 0.6× 334 1.0× 59 1.8k
Matthias Heck Germany 30 1.9k 1.3× 3.0k 2.0× 769 0.8× 431 1.0× 545 1.7× 93 3.8k
Amir Iravani Australia 27 2.2k 1.4× 2.1k 1.4× 1.1k 1.1× 313 0.7× 167 0.5× 108 3.2k
Hans‐Juergen Wester Germany 22 1.1k 0.7× 864 0.6× 716 0.7× 151 0.4× 223 0.7× 38 2.0k
Francesco Ceci Italy 29 2.1k 1.4× 2.8k 1.9× 510 0.5× 391 0.9× 256 0.8× 128 3.4k

Countries citing papers authored by Justin Ferdinandus

Since Specialization
Citations

This map shows the geographic impact of Justin Ferdinandus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin Ferdinandus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin Ferdinandus more than expected).

Fields of papers citing papers by Justin Ferdinandus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin Ferdinandus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin Ferdinandus. The network helps show where Justin Ferdinandus may publish in the future.

Co-authorship network of co-authors of Justin Ferdinandus

This figure shows the co-authorship network connecting the top 25 collaborators of Justin Ferdinandus. A scholar is included among the top collaborators of Justin Ferdinandus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin Ferdinandus. Justin Ferdinandus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferdinandus, Justin, Michael Fuchs, Hans Theodor Eich, et al.. (2024). Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials. Blood. 144(Supplement 1). 566–566. 1 indexed citations
2.
Pabst, Kim M., Lukas Kessler, Justin Ferdinandus, et al.. (2024). [68Ga]Ga-FAPI versus 2-[18F]FDG PET/CT in patients with autoimmune thyroiditis: a case control study. EJNMMI Research. 14(1). 66–66. 2 indexed citations
3.
Ferdinandus, Justin, Katrin Roth, Markus Dietlein, et al.. (2023). Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group. European Journal of Nuclear Medicine and Molecular Imaging. 51(2). 490–495. 4 indexed citations
4.
Kessler, Lukas, Nader Hirmas, Kim M. Pabst, et al.. (2023). 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the68Ga-FAPI PET Observational Trial. Journal of Nuclear Medicine. 64(12). 1910–1917. 13 indexed citations
5.
Müller, Horst, Jasmin Mettler, Christian Baues, et al.. (2023). Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial. European Journal Of Haematology. 111(6). 881–887. 6 indexed citations
6.
Fendler, Wolfgang P., Kim M. Pabst, Lukas Kessler, et al.. (2022). Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clinical Cancer Research. 28(19). 4346–4353. 91 indexed citations
7.
Seifert, Robert, David Kersting, Christoph Rischpler, et al.. (2022). Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial. Leukemia. 36(12). 2845–2852. 4 indexed citations
8.
Seifert, Robert, Wolfgang P. Fendler, Hubertus Hautzel, et al.. (2022). A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. Seminars in Nuclear Medicine. 52(6). 816–823. 8 indexed citations
9.
Ferdinandus, Justin, Wolfgang P. Fendler, Andrea Farolfi, et al.. (2021). PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine. 63(1). 76–80. 24 indexed citations
10.
Weber, Manuel, Boris Hadaschik, Justin Ferdinandus, et al.. (2021). Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate Cancer. European Urology Focus. 7(2). 279–287. 17 indexed citations
11.
Barbato, Francesco, Wolfgang P. Fendler, Isabel Rauscher, et al.. (2021). PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. Journal of Nuclear Medicine. 62(12). 1747–1750. 24 indexed citations
12.
Kessler, Lukas, Justin Ferdinandus, Nader Hirmas, et al.. (2021). Pitfalls and Common Findings in68Ga-FAPI PET: A Pictorial Analysis. Journal of Nuclear Medicine. 63(6). 890–896. 72 indexed citations
13.
Ferdinandus, Justin, Wolfgang P. Fendler, Jérémie Calais, et al.. (2020). Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. European Urology Open Science. 19. e1215–e1216. 2 indexed citations
14.
Ferdinandus, Justin, John Violet, Shahneen Sandhu, et al.. (2020). Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. 47(10). 2322–2327. 115 indexed citations
15.
Wegen, Simone, et al.. (2020). Managing patient flows in radiation oncology during the COVID-19 pandemic. Strahlentherapie und Onkologie. 196(12). 1080–1085. 14 indexed citations
16.
Ferdinandus, Justin, Francesco Barbato, Wolfgang P. Fendler, et al.. (2020). Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. Journal of Nuclear Medicine. 62(2). 191–194. 14 indexed citations
17.
Ferdinandus, Justin, Wolfgang P. Fendler, Jérémie Calais, et al.. (2020). Impact of 68 Ga-PSMA-11 PET on the Management of biochemically recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Nuklearmedizin - NuclearMedicine. 2 indexed citations
18.
Siebermair, Johannes, Stephan G. Nekolla, Lukas Kessler, et al.. (2020). Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. Journal of Nuclear Cardiology. 28(3). 812–821. 75 indexed citations
19.
Hofman, Michael S., John Violet, Rodney J. Hicks, et al.. (2018). [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. The Lancet Oncology. 19(6). 825–833. 815 indexed citations breakdown →
20.
Violet, John, Price Jackson, Justin Ferdinandus, et al.. (2018). Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Journal of Nuclear Medicine. 60(4). 517–523. 339 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carsten Kobe Breakdown of academic impact, for papers by Jérémie Calais Breakdown of academic impact, for papers by Laura Evangelista Breakdown of academic impact, for papers by Sanjana Ballal Breakdown of academic impact, for papers by Hendrik Rathke Breakdown of academic impact, for papers by Madhav Prasad Yadav Breakdown of academic impact, for papers by Matthias Heck Breakdown of academic impact, for papers by Amir Iravani Breakdown of academic impact, for papers by Hans‐Juergen Wester Breakdown of academic impact, for papers by Francesco Ceci
Rankless by CCL
2026